RxDoctor Payments Data

Mandeep Bhamra, MD

Gastroenterology · Albany, NYNPI 1942465653

Payments from drug & device makers

$43,858in general payments, 2019–2025

Across 140 payments — averaging $313.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$42K
  • Creo Medical Inc.$462
  • AbbVie$257
  • Ardelyx, Inc.$183
  • E.r. Squibb & Sons, L.L.C.$128
  • Janssen Scientific Affairs, LLC$121
  • plus $249 from 6 others

What the payments were for

  • Consulting fees$25,10057%
  • Speaking & faculty fees$8,92020%
  • Grants$200%
  • Travel & lodging$6,83616%
  • Food & beverage$2,9827%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,858 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$160,550
Medicare patients
338
Services billed
4,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$341,101
CreonLipase/Protease/Amylase49$92,014
LinzessLinaclotide25$25,277
Ursodiol18$5,760
Sucralfate60$5,735
Pantoprazole Sodium111$1,700
Dicyclomine Hcl44$1,646
Omeprazole151$1,491
Famotidine105$1,353
Lubiprostone12$941
Lansoprazole14$700
Spironolactone11$254
Amitriptyline Hcl17$189
Prednisone13$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$17$341,10112 claims
AbbVieCreon, Linzess$257$117,29174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →